
The Uncertain Future of mRNA Vaccines in the Flu Shot Market
Pharmaceutical companies that developed mRNA vaccines for COVID-19 are now exploring the flu vaccine market, which relies on an outdated production process. The advantages of mRNA flu shots include the potential for more accurate strain selection, quicker production timelines, and improved effectiveness. Additionally, mRNA vaccines could address supply issues during flu pandemics. However, challenges include public acceptance of mRNA technology, potential side effects, high costs, and a crowded market. The jury is still out on the effectiveness of combination vaccines for flu, COVID-19, and RSV. Experts believe that the mRNA platform has the potential to revolutionize flu vaccines, but further research and regulatory approval are needed to develop vaccines with longer-lasting and broader protection.
